This company has been acquired
Enhabit (EHAB) Aktienübersicht
Enhabit, Inc. bietet häusliche Gesundheits- und Hospizdienste in den Vereinigten Staaten an. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 5/6 |
| Künftiges Wachstum | 3/6 |
| Vergangene Leistung | 0/6 |
| Finanzielle Gesundheit | 3/6 |
| Dividenden | 0/6 |
EHAB Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Enhabit, Inc. Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | US$13.80 |
| 52-Wochen-Hoch | US$14.22 |
| 52-Wochen-Tief | US$6.47 |
| Beta | 0.96 |
| 1 Monat Veränderung | 0.51% |
| 3 Monate Veränderung | 23.66% |
| 1 Jahr Veränderung | 29.70% |
| 3 Jahre Veränderung | 16.06% |
| 5 Jahre Veränderung | n/a |
| Veränderung seit IPO | -44.80% |
Aktuelle Nachrichten und Updates
EHAB: Kinderhook Cash Offer And Deal Completion Will Shape Forward Risk Balance
Analysts have aligned Enhabit’s updated fair value estimate with the agreed Kinderhook Industries takeout price, trimming the target by $0.03 to $13.80 as they factor in the all cash $13.80 per share acquisition and modest tweaks to growth, margin and discount rate assumptions. Analyst Commentary Street research has largely converged around Enhabit’s agreed takeout price, with multiple firms resetting ratings and targets to align with the US$13.80 per share all cash offer from Kinderhook Industries.EHAB: Cash Sale Terms And Reimbursement Backdrop Will Shape Forward Risk Balance
Analysts have inched their average price target for Enhabit up by about $0.03 to roughly $13.83, reflecting recent research that aligns estimates with the agreed all cash acquisition price of $13.80 per share. Analyst Commentary Recent research on Enhabit has shifted quickly after the announced all cash acquisition at $13.80 per share, with most commentary now centered on how closely the stock aligns with the agreed deal value rather than on long term standalone upside.EHAB: Kinderhook Cash Deal And Reimbursement Backdrop Will Shape Forward Risk Balance
Analysts have adjusted Enhabit’s price target to $13.80 per share, in line with the agreed all cash acquisition price from Kinderhook Industries. They cite the pending takeout and recent shifts in ratings to Hold, Neutral, Perform and Market Perform at multiple firms as the key drivers of this update.Recent updates
EHAB: Kinderhook Cash Offer And Deal Completion Will Shape Forward Risk Balance
Analysts have aligned Enhabit’s updated fair value estimate with the agreed Kinderhook Industries takeout price, trimming the target by $0.03 to $13.80 as they factor in the all cash $13.80 per share acquisition and modest tweaks to growth, margin and discount rate assumptions. Analyst Commentary Street research has largely converged around Enhabit’s agreed takeout price, with multiple firms resetting ratings and targets to align with the US$13.80 per share all cash offer from Kinderhook Industries.EHAB: Cash Sale Terms And Reimbursement Backdrop Will Shape Forward Risk Balance
Analysts have inched their average price target for Enhabit up by about $0.03 to roughly $13.83, reflecting recent research that aligns estimates with the agreed all cash acquisition price of $13.80 per share. Analyst Commentary Recent research on Enhabit has shifted quickly after the announced all cash acquisition at $13.80 per share, with most commentary now centered on how closely the stock aligns with the agreed deal value rather than on long term standalone upside.EHAB: Kinderhook Cash Deal And Reimbursement Backdrop Will Shape Forward Risk Balance
Analysts have adjusted Enhabit’s price target to $13.80 per share, in line with the agreed all cash acquisition price from Kinderhook Industries. They cite the pending takeout and recent shifts in ratings to Hold, Neutral, Perform and Market Perform at multiple firms as the key drivers of this update.EHAB: Kinderhook Cash Takeout And Sector Reimbursement Trends Will Shape Forward Risk Balance
The analyst price target for Enhabit has been adjusted from $13.08 to $13.80. Analysts cite the agreed all-cash acquisition by Kinderhook Industries at $13.80 per share as the primary reference point for the valuation.Enhabit: Why This Healthcare Buyout Won't Raise FTC Alarms
Summary Enhabit Inc. is being acquired by Kinderhook Industries for $13.80 per share, an all-cash deal at an enterprise valuation of $1.1 billion. I see minimal antitrust risk, as Kinderhook lacks significant overlap in hospice care, making regulatory intervention unlikely. EHAB trades at a discount to peers due to higher debt and inconsistent profitability, but the acquisition premium reflects limited market optimism. With only a 1.8% spread to the deal price and limited upside, I rate EHAB a Hold pending deal completion. Read the full article on Seeking AlphaEHAB: Takeout At 13.80 And Reimbursement Clarity Will Shape Forward Risk Balance
The analyst price target for Enhabit has been raised from $11.75 to $13.08. Analysts cited the agreed all-cash acquisition at $13.80 per share and related updates to assumed future P/E as the key drivers of the change.EHAB: Clearer Reimbursement And Mixed Ratings Will Shape Forward Risk Balance
Narrative Update on Enhabit The analyst price target for Enhabit has moved to $11.75. Analysts note that clearer home health reimbursement rules, an improved regulatory backdrop, and what they describe as a discounted valuation support a more constructive stance on the shares.EHAB: Clearer Reimbursement And Mixed Ratings Will Shape Future Earnings Visibility
Narrative Update The analyst price target for Enhabit has shifted from $10.60 to $11.75, as analysts factor in an improved home health reimbursement backdrop, clearer earnings visibility, and reduced regulatory overhang reflected in recent upgrades and higher targets around $12. Analyst Commentary Recent research on Enhabit has turned more positive, with several firms lifting ratings and price targets to around US$12 as the regulatory picture for home health reimbursement becomes clearer.EHAB: Final Rule Clarity And Mixed Ratings Will Shape Earnings Outlook
Analysts have lifted their price expectations for Enhabit, with our fair value estimate moving from US$9.38 to US$10.60. They point to greater earnings clarity following the final home health rule, a modest adjustment to discount rates and profit assumptions, and recent research that highlights both improving operations and what some see as a discounted valuation.Aging Demographics Will Fuel US Home Care Expansion
Despite a notable improvement in net profit margin and a lower future P/E ratio, the consensus analyst price target for Enhabit has been reduced from $10.00 to $9.38. What's in the News Enhabit, Inc.Enhabit, Inc. (NYSE:EHAB) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough
Enhabit, Inc. ( NYSE:EHAB ) shareholders won't be pleased to see that the share price has had a very rough month...Enhabit (NYSE:EHAB) Has A Pretty Healthy Balance Sheet
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...US Home Health Demand And Value-Based Care Will Create Future Opportunities
Structural trends and targeted expansion in underserved markets are driving sustained revenue growth and building a reliable recurring revenue base.Returns On Capital At Enhabit (NYSE:EHAB) Paint A Concerning Picture
When we're researching a company, it's sometimes hard to find the warning signs, but there are some financial metrics...Enhabit, Inc.'s (NYSE:EHAB) Revenues Are Not Doing Enough For Some Investors
When you see that almost half of the companies in the Healthcare industry in the United States have price-to-sales...Enhabit: Healthcare Predictive Analytics, FCF, Very Undervalued
Summary EHAB's investments in healthcare predictive analytics, expected to grow at 23%-24% CAGR, could significantly boost future net income growth. Restructuring, activism, and strategic reviews are potential catalysts for stock price appreciation, enhancing financial flexibility from 2025 to 2030. Despite recent negative net income, EHAB's consistent positive cash flow and undervaluation indicate substantial upside potential in stock price. Valuation models suggest higher upside potential, with best case scenario implying a target price of $11-$12 per share. Read the full article on Seeking AlphaIs Enhabit (NYSE:EHAB) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Returns On Capital At Enhabit (NYSE:EHAB) Paint A Concerning Picture
If you're looking at a mature business that's past the growth phase, what are some of the underlying trends that pop...Is Enhabit (NYSE:EHAB) Using Too Much Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Is Enhabit Dead? Not Quite Yet
Summary It is soon to be the last independent home health and hospice company. Scarcity value could drive interest from financial and strategic bidders. Shareholders have a slate of new directors to refresh the company. Read the full article on Seeking AlphaEnhabit (NYSE:EHAB) Could Be At Risk Of Shrinking As A Company
When it comes to investing, there are some useful financial metrics that can warn us when a business is potentially in...An Intrinsic Calculation For Enhabit, Inc. (NYSE:EHAB) Suggests It's 42% Undervalued
Key Insights Using the 2 Stage Free Cash Flow to Equity, Enhabit fair value estimate is US$14.19 Enhabit is estimated...Here's What Analysts Are Forecasting For Enhabit, Inc. (NYSE:EHAB) After Its Annual Results
It's been a pretty great week for Enhabit, Inc. ( NYSE:EHAB ) shareholders, with its shares surging 17% to US$10.34 in...The Market Doesn't Like What It Sees From Enhabit, Inc.'s (NYSE:EHAB) Revenues Yet
You may think that with a price-to-sales (or "P/S") ratio of 0.4x Enhabit, Inc. ( NYSE:EHAB ) is a stock worth checking...Enhabit (NYSE:EHAB) Could Be Struggling To Allocate Capital
To avoid investing in a business that's in decline, there's a few financial metrics that can provide early indications...Aktionärsrenditen
| EHAB | US Healthcare | US Markt | |
|---|---|---|---|
| 7D | 0.07% | -1.2% | 2.0% |
| 1Y | 29.7% | 16.8% | 23.3% |
Rendite im Vergleich zur Industrie: EHAB übertraf die Branche US Healthcare , die im vergangenen Jahr eine Rendite von 16.8 erzielte.
Rendite vs. Markt: EHAB übertraf den Markt US, der im vergangenen Jahr eine Rendite von 23.3 erzielte.
Preisvolatilität
| EHAB volatility | |
|---|---|
| EHAB Average Weekly Movement | 6.6% |
| Healthcare Industry Average Movement | 7.0% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stabiler Aktienkurs: EHAB hatte in den letzten 3 Monaten im Vergleich zum US -Markt keine signifikante Preisvolatilität.
Volatilität im Zeitverlauf: EHABDie wöchentliche Volatilität (7%) ist im vergangenen Jahr stabil geblieben.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 1998 | 10,800 | Barb Jacobsmeyer | www.ehab.com |
Enhabit, Inc. bietet häusliche Gesundheits- und Hospizdienste in den Vereinigten Staaten an. Das Segment "Häusliche Krankenpflege" bietet Krankenpflege, Physio-, Ergo- und Sprachtherapie, medizinische und soziale Arbeit sowie häusliche Krankenpflegeassistenz an. Dieses Segment bietet auch Patientenaufklärung, Schmerzmanagement, Wundversorgung und Verbandswechsel, kardiologische Rehabilitation, Infusionstherapie, pharmazeutische Verabreichung und qualifizierte Beobachtungs- und Beurteilungsdienste; Praktiken zur Behandlung chronischer Krankheiten und Zustände, einschließlich Diabetes, Bluthochdruck, Arthritis, Alzheimer-Krankheit, Sehschwäche, Spinalkanalstenose, Parkinson-Krankheit, Osteoporose, komplexe Wundversorgung und chronische Schmerzen, zusammen mit krankheitsspezifischen Plänen für Patienten mit Diabetes, Herzinsuffizienz, nach orthopädischen Operationen oder Verletzungen und Atemwegserkrankungen; und Beratung für Patienten und ihre Familien in Bezug auf finanzielle, persönliche und soziale Belange, die sich aus den gesundheitlichen Problemen eines Patienten ergeben.
Enhabit, Inc.'s Grundlagenzusammenfassung
| EHAB grundlegende Statistiken | |
|---|---|
| Marktanteil | US$706.91m |
| Gewinn(TTM) | -US$3.20m |
| Umsatz(TTM) | US$1.06b |
Ist EHAB zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| EHAB Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$1.06b |
| Kosten der Einnahmen | US$544.20m |
| Bruttogewinn | US$520.70m |
| Sonstige Ausgaben | US$523.90m |
| Gewinn | -US$3.20m |
Zuletzt gemeldete Gewinne
Mar 31, 2026
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | -0.062 |
| Bruttomarge | 48.90% |
| Nettogewinnspanne | -0.30% |
| Schulden/Eigenkapital-Verhältnis | 72.7% |
Wie hat sich EHAB auf lange Sicht entwickelt?
Historische Performance und VergleicheUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/05/16 22:29 |
| Aktienkurs zum Tagesende | 2026/05/14 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Enhabit, Inc. wird von 7 Analysten beobachtet. 4 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Joanna Sylvia Gajuk | BofA Global Research |
| Jason Cassorla | Citigroup Inc |
| Jamie Perse | Goldman Sachs |